0O8G Stock Chart & Stats
€3.02
€0.00(0.00%)
At close: 4:00 PM EDT
€3.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.02 - €3.02
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€61.93M
Enterprise Value€107.73
Total Cash (Recent Filing)€29.03M
Total Debt (Recent Filing)€95.11M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding95,417,380
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.28Price Target Upside-57.48% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.43
Revenue Forecast (FY)€95.07M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Commercial MomentumSustained revenue expansion and reiterated growth guidance indicate improving adoption of MDxHealth’s diagnostic portfolio. Sequential acceleration and customer transitions support a potentially larger commercial base over the next several quarters.
Healthy Gross MarginsGross margins remain strong for a diagnostics business, supporting attractive economics as test volumes scale. Although product mix caused recent compression, the underlying margin profile provides a foundation for operating leverage and eventual profitability.
Clinical And Product Development DepthPeer-reviewed clinical evidence and continued research can strengthen physician confidence, reimbursement support, and differentiation in urologic diagnostics. AI initiatives may also expand the value of the platform across existing customers and future product offerings.
Bears Say
Persistent Losses And Negative Cash FlowThe company remains dependent on external capital because operations do not yet generate sufficient cash. Continued net losses and negative free cash flow could limit investment flexibility and increase financing needs before management’s profitability target is reached.
Leveraged And Weakened Capital StructureHigher debt combined with negative equity signals limited balance-sheet resilience and raises refinancing, covenant, and dilution risk. This structure could constrain strategic execution if operating improvements take longer than expected or additional capital is required.
Margin And Tissue-Volume Execution PressureThe product mix shift and weaker year-over-year tissue momentum create uncertainty around revenue quality and margin sustainability. Higher ExoDx-related costs further delay operating leverage, making the path to positive EBITDA dependent on volume recovery and integration.
MDxHealth News
0O8G FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest share price was €3.02 and its highest was €3.02 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is €61.93M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is Nov 12, 2026 which is in 76 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on Aug 13, 2026. The company reported -€0.154 earnings per share for the quarter, beating the consensus estimate of -€0.165 by €0.011.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Overvalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.08.
How many shares outstanding does MDxHealth have?
MDxHealth has 95,417,380 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -€0.154 in its last earnings report, beating expectations of -€0.165. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in GB:0O8G
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MDxHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1.28 (-57.48% Downside)
€1.28 (-57.48% Downside)
Blogger Sentiment
Neutral
GB:0O8G Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €849.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.08%
Trailing 12-Months
Company Description
MDxHealth
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
0O8G Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of strong operational and strategic progress — significant sequential revenue acceleration, a successful customer transition, removal of a $10.4M contingent liability, clinical data momentum, and a $20M capital raise — alongside meaningful near-term financial challenges including wider operating and net losses, negative adjusted EBITDA, gross margin compression, and tissue volumes still down year-over-year. Management reiterated full-year revenue guidance ($110M–$115M) and a path to adjusted EBITDA positivity by year-end, striking an overall tone of cautious optimism while acknowledging current profitability headwinds.View all GB:0O8G earnings summaries0O8G Stock 12 Month Forecast
Average Price Target
€1.28
▼(-57.48% Downside)